Oncology Final

  1. Breast Cancer
    When should paclitaxel be added to doxorubicin and cyclophosphamide in adjuvant treatment?
    Her(+) or LN(+)
  2. Breast Cancer
    Lapatinib is only used in which setting?
    Metastatic disease
  3. Breast Cancer
    New first-line combination for metastatic disease?
    Palbociclib and letrozole
  4. Colorectal Cancer
    Bevacizumab and the FOLFIRI regimen should only be used in which setting?
    Metastatic disease
  5. Colorectal Cancer
    Which anti-EGFR mabs should only be used in the metastatic setting?
    Cetuximab and panituzumab
  6. NSCLC
    Platinols and vinorelbine are standard chemotherapy.  Which additional agent should be used in adenocarcinoma only?
  7. NSCLC
    First-line agents prior to chemotherapy in patients who are EGFR(+)?
    Erlotinib and afatinib
  8. NSCLC
    EML4-ALK inhibitors like crizotinib should be used in which cellular type of NSCLC?
  9. NSCLC
    Choice agents for maintenance to prevent disease progression once stable?
    Pemetrexed +/- bevacizumab, erlotinib, or gemcitabine
  10. SCLC
    Gold-standard treatment?
    Cisplatin and IV etoposide
  11. Non-Hodgkin Lymphoma
    B-cell lymphomas usually present in the lymph nodes, spleen, and marrow.  Where do T-cell lymphomas present?
    Extranodal sites like skin and lungs
  12. DLBCL
    What are the components of R-CHOP?
    • Rituximab
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Prednisone
  13. Indolent Lymphoma
    Which agent can be used alone if the FLIPI score is low?
  14. Follicular Lymphoma
    R-CHOP is a possible therapeutic option, as is bendamustine + Rituximab.  What is R-CVP?
    R-CHOP without doxorubicin: Cyclophosphamide, vincristine, and prednisone
  15. Non-Hodgkin Lymphoma
    Rituximab maintenance considerations?
    Check HepB serology and CD4 counts
  16. Non-Hodgkin Lymphoma
    T-cell lymphomas can be treated with CHOP.  Why is rituximab omitted?
    T-cells do not express CD20
  17. CML
    What is the important genetic marker in CML?
    Philadelphia chromosome/BCR-ABL
  18. CML
    Therapeutic alternative for patients intolerant to 2+ TKIs?
    Omacetaxine mepesuccinate
  19. CLL
    Which cytogenetic abnormalities are important in CLL?
    17p deletion and 11q deletion
  20. CLL
    Therapy progression for CLL?
    Chlorambucil -> purine analogs -> CD20 mabs (maybe with chlorambucil) -> ibrutinib/idelaslib or bendamustine with rituximab
  21. CLL
    Which agent can cause A-fib, an increase in lymphocyte count, and should be held prior to surgeries?
  22. AML
    Gold standard treatment?
    3 days anthracycline plus 7 days of low-dose cytarabine
  23. AML
    Common post-remission therapeutic plan?
    HiDAC x 4 cycles
  24. APL/AML M3
    With what do most patients present?
    Bleeding diathesis
  25. APL/AML M3
    Gold standard treatment?
    ATRA + Arsenic/Chemotherapy
  26. ALL
    Which drug is unique to this indication?
Card Set
Oncology Final
py3 onco final